Clinical Trial Update: Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of enadenotucirev given via sub-acute fractionated IV dosing in cancer patients (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Solid Tumours of Epithelial Origin

Drugs mentioned

• Enadenotucirev (enadenotucirev)

Snippet

Sponsor: Akamis Bio | Conditions: Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED